Changes in Eye Pressure and Anterior Chamber Depth With Oral Endothelin Antagonist Therapy
NCT ID: NCT00452283
Last Updated: 2013-01-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
23 participants
OBSERVATIONAL
2007-03-31
2011-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
We hypothesize that the rate of structural damage to the NFL, a feature of glaucoma, is higher in patients with PH than expected in healthy populations lacking this disease.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Aqueous Suppressant Versus Aqueous Outflow on Ocular Blood Flow
NCT01308788
Choroidal Thickness During Changes in Intraocular Pressure and Arterial Blood Pressure
NCT01333891
Effects of Non-Specific Endothelin-A Receptor Blockade on Ocular Blood Flow in Patients With Glaucoma
NCT00701597
Circadian Variations in Ocular Blood Flow in Glaucomatous and Normal Eyes
NCT00707226
Inhaled Corticosteroids: Effect on Intraocular Pressure in Patients With Controlled Glaucoma
NCT02338362
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* between the ages of 18 and 80 years
* ability to undergo the various ocular exams.
Exclusion Criteria
* special populations; ie children, pregnancy, lactating females, prisoners
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Colorado, Denver
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Malik Y. Kahook, M.D.
Role: PRINCIPAL_INVESTIGATOR
University of Colorado School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Colorado Eye Center
Aurora, Colorado, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
06-0792
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.